DK0672116T3 - Deletionsmutanter som vacciner mod kolera - Google Patents

Deletionsmutanter som vacciner mod kolera

Info

Publication number
DK0672116T3
DK0672116T3 DK93916907T DK93916907T DK0672116T3 DK 0672116 T3 DK0672116 T3 DK 0672116T3 DK 93916907 T DK93916907 T DK 93916907T DK 93916907 T DK93916907 T DK 93916907T DK 0672116 T3 DK0672116 T3 DK 0672116T3
Authority
DK
Denmark
Prior art keywords
cholera
vaccine
deletion mutants
cholerae
oral
Prior art date
Application number
DK93916907T
Other languages
Danish (da)
English (en)
Inventor
Kevin Killeen
David Beattie
Yichen Lu
John J Mekalanos
Original Assignee
Avant Immunotherapeutics Inc
Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avant Immunotherapeutics Inc, Harvard College filed Critical Avant Immunotherapeutics Inc
Application granted granted Critical
Publication of DK0672116T3 publication Critical patent/DK0672116T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/107Vibrio
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/28Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Vibrionaceae (F)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72Receptors; Cell surface antigens; Cell surface determinants for hormones
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20Bacteria; Culture media therefor
    • C12N1/205Bacterial isolates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/01Preparation of mutants without inserting foreign genetic material therein; Screening processes therefor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541Mucosal route
    • A61K2039/542Mucosal route oral/gastrointestinal
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12RINDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00Microorganisms ; Processes using microorganisms
    • C12R2001/01Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/63Vibrio
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00Chemistry: molecular biology and microbiology
    • Y10S435/8215Microorganisms
    • Y10S435/822Microorganisms using bacteria or actinomycetales
    • Y10S435/909Vibrio

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK93916907T 1992-07-06 1993-07-01 Deletionsmutanter som vacciner mod kolera DK0672116T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90938292A 1992-07-06 1992-07-06
PCT/US1993/006270 WO1994001533A1 (en) 1992-07-06 1993-07-01 Deletion mutants as vaccines for cholera

Publications (1)

Publication Number Publication Date
DK0672116T3 true DK0672116T3 (da) 2003-10-06

Family

ID=25427152

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93916907T DK0672116T3 (da) 1992-07-06 1993-07-01 Deletionsmutanter som vacciner mod kolera

Country Status (16)

Country Link
US (1) US5631010A (de)
EP (1) EP0672116B1 (de)
JP (2) JP4179627B2 (de)
CN (1) CN1083524A (de)
AT (1) ATE242319T1 (de)
AU (1) AU4660893A (de)
BR (1) BR9306707A (de)
CA (1) CA2139655C (de)
DE (1) DE69333028T2 (de)
DK (1) DK0672116T3 (de)
ES (1) ES2199944T3 (de)
MX (1) MX9303992A (de)
PT (1) PT672116E (de)
TW (1) TW266228B (de)
WO (1) WO1994001533A1 (de)
ZA (1) ZA934736B (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5882653A (en) * 1983-03-04 1999-03-16 The University Of Maryland System Vibrio cholerae 01 (CVD111) and non-01 (CVD112 and CVD112RM) serogroup vaccine strains, methods of making same and products thereof
EP0692031B1 (de) * 1993-02-22 2007-04-11 The General Hospital Corporation Heterologe antigene in stämmen zur impfung mit lebendzellen
US6203799B1 (en) 1993-07-01 2001-03-20 Presidents And Fellows Of Harvard College Vibrio cholerae mutants which are soft-agar penetration defective and lack a functional CtxA subunit
CA2173606A1 (en) * 1993-10-08 1995-04-20 James B. Kaper Vibrio cholerae 01 (cvd111) and non-01 (cvd112 and cvd112rm) serogroup vaccine strains, methods of making same and products thereof
CN1058522C (zh) * 1994-04-01 2000-11-15 中国预防医学科学院流行病学微生物研究所 一种霍乱弧菌新菌株及其活菌苗
US6887483B2 (en) * 1995-12-01 2005-05-03 University Of Iowa Research Foundation Non-toxic mutants of pathogenic gram-negative bacteria
WO1998023763A1 (en) * 1996-11-29 1998-06-04 The General Hospital Corporation Heterologous antigens in live cell v. cholerae strains
JP4086945B2 (ja) * 1996-12-10 2008-05-14 カウンシル・オブ・サイエンティフィック・アンド・インダストリアル・リサーチ 非毒性V.Cholerae株の単離法およびその株由来のコレラワクチンの製造法
US6818222B1 (en) 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
EP0887403A3 (de) * 1997-06-27 2000-12-06 Chiron S.P.A. Abgeschwächte Stämme von Vibrio cholerae
EP0928831B1 (de) * 1997-12-10 2006-05-03 Council of Scientific and Industrial Research Choleraorganismen, Impfstoffe und ihre Verwendung
FR2772791B1 (fr) * 1997-12-24 2000-01-28 Staubli Sa Ets Actionneur rotatif electrique pour la formation de la foule sur un metier a tisser, mecanique d'armure et metier a tisser
US6686339B1 (en) 1998-08-20 2004-02-03 Aventis Pasteur Limited Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia
US6693087B1 (en) 1998-08-20 2004-02-17 Aventis Pasteur Limited Nucleic acid molecules encoding POMP91A protein of Chlamydia
CA2340330A1 (en) 1998-08-20 2000-03-02 Aventis Pasteur Limited Nucleic acid molecules encoding inclusion membrane protein c of chlamydia
US6592869B2 (en) * 1999-08-24 2003-07-15 Teva Pharmaceutical Industries, Ltd. Vaccine composition and method of using the same
PL364983A1 (en) * 1999-08-24 2004-12-27 Teva Pharmaceutical Industries, Ltd. A vaccine composition and method of using the same
ATE395930T1 (de) 1999-10-22 2008-06-15 Aventis Pasteur Verfahren zur erregung und/oder verstärkung der immunantwort gegen tumorantigene
EP1792995A3 (de) 2000-05-08 2007-06-13 Sanofi Pasteur Limited Chlamydia Antigene, entsprechende DNS Fragmente und ihre Verwendungen
DK1282702T3 (da) 2000-05-10 2007-04-02 Sanofi Pasteur Ltd Immunogene polypeptider, som er kodet af KAGE-minigener, og anvendelser deraf
CN1484700A (zh) 2000-11-02 2004-03-24 �¼��¹�����ѧ aopB基因,蛋白,同系物,片段和它们的变体,以及它们在细胞表面展示方面的应用
EP1864691B1 (de) 2002-04-09 2011-07-20 Sanofi Pasteur Limited Modifizierte CEA-Nukleinsäure und entsprechende Expressionsvektoren
AU2004280608B2 (en) * 2002-04-09 2012-04-05 Sanofi Pasteur, Inc. Modified CEA/B7 vector
US20060099229A1 (en) * 2004-11-05 2006-05-11 Universiti Sains Malaysia Vibrio cholerae strains VCUSM1 and VCUSM4, method of producing same, and vaccine derivatives thereof
EP1543836A1 (de) * 2003-12-17 2005-06-22 Berna Biotech AG Rekombinante Stamm von Vibrio cholerae und Impfstoff, der diesem Stamm enthält
CN101730737B (zh) * 2007-04-24 2016-06-01 赛尔戴克斯治疗公司 超表达重组霍乱毒素b亚单位的霍乱弧菌显示双重免疫原性
CN101519440B (zh) * 2008-02-29 2012-02-08 中国科学院海洋研究所 一种交叉保护性疫苗抗原及其制备方法和应用
JP2013505017A (ja) * 2009-09-16 2013-02-14 ゴトバックス アーベー コレラおよび毒素原性大腸菌(etec)下痢に対するワクチン
CN103468623B (zh) * 2011-09-30 2016-01-06 中山百慧基因科技有限公司 基因工程用工具菌及其应用
US11136358B2 (en) 2016-12-16 2021-10-05 Industry-University Cooperation Foundation Hanyang University Erica Campus Plasmid-based CTX phage replication system and vibrio cholerae strain that can be infected by CTX phage and can be used for cholera toxin production
WO2018111018A2 (ko) * 2016-12-16 2018-06-21 한양대학교 에리카산학협력단 플라스미드 기반의 ctx 파지 복제시스템 및 ctx 파지에 감염되고 콜레라 독소를 생산할 수 있는 비브리오 콜레라 균주
JP7231607B2 (ja) * 2017-07-12 2023-03-01 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド プロバイオティクスの性質を有する弱毒生コレラワクチン

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4935364A (en) * 1983-03-04 1990-06-19 Swiss Serum And Vaccine Institute Berne Method of isolating restriction fragment deletions in vibrio cholerae and products thereof
US4882278A (en) * 1983-04-29 1989-11-21 President And Fellows Of Harvard College Non-toxinogenic vibrio cholerae mutants
US5098998A (en) * 1987-04-29 1992-03-24 President And Fellows Of Harvard College Cholera vaccines and peptides
AU656730B2 (en) * 1990-06-05 1995-02-16 University Of Maryland At Baltimore Method of isolating restriction fragment deletions in vibrio cholerae, and products thereof

Also Published As

Publication number Publication date
EP0672116B1 (de) 2003-06-04
BR9306707A (pt) 1998-12-08
EP0672116A4 (de) 1996-06-12
DE69333028D1 (de) 2003-07-10
CA2139655A1 (en) 1994-01-20
PT672116E (pt) 2003-10-31
TW266228B (de) 1995-12-21
JPH07508885A (ja) 1995-10-05
ATE242319T1 (de) 2003-06-15
AU4660893A (en) 1994-01-31
EP0672116A1 (de) 1995-09-20
CA2139655C (en) 2008-05-13
MX9303992A (es) 1995-01-31
ES2199944T3 (es) 2004-03-01
JP2004159660A (ja) 2004-06-10
US5631010A (en) 1997-05-20
DE69333028T2 (de) 2004-04-22
ZA934736B (en) 1994-01-24
WO1994001533A1 (en) 1994-01-20
CN1083524A (zh) 1994-03-09
JP4179627B2 (ja) 2008-11-12

Similar Documents

Publication Publication Date Title
DK0672116T3 (da) Deletionsmutanter som vacciner mod kolera
DK0865297T3 (da) Vaccinesammensætninger til intranasal administration omfattende chitosan og anvendelsen deraf
DK0877624T3 (da) Vaccine med udgangspunkt i streptokokkisk C5A-peptidase
EP1170016A3 (de) Impfstoff auf Urease-Basis gegen Helicobacter Infektionen
CA2082155A1 (en) Swine pneumonia vaccine and method of preparation
FI970799A0 (fi) Mutanttientoroksiini, joka on tehokas ei-toksinen oraalinen adjuvantti
IL91525A0 (en) Transgenic plants,pharmaceutical compositions containing the same and methods for the preparation thereof
AU2145188A (en) Therapeutic compositions against streptococcal infections, transformed hosts, methods of immunization and genetically engineered products
SE9003198D0 (sv) Fish vaccine comprising a virulent, invasive bacterium
NZ335050A (en) Helicobacter pylori live vaccine
DK0757556T3 (da) Borrelia Burgdorferi-bakterin
CA2222482A1 (en) Non-virulent mycoplasma synoviae and vaccine thereof
SE9604322D0 (sv) Bacterial antigens and vaccine compositions II
DK0603386T3 (da) Parenteral immunisering mod rotavirus
NO913131L (no) Immunogene konjugater av ikke-toksisk oligosakkarid fra bordetella pertussis lipoolysakkarid.
NO996428L (no) Anti-Vibrio anguillarum-vaksine (GAVA-3) for forhindring av vibriosen i piggvar og laksefisk og fremgangsmåten for fremstilling av slike vaksiner
IT8722791A0 (it) Attenuato cosi' ottenuto. procedimento per la preparazione di un ceppo mutante migliorato di bordetella bronchiseptica utile per un vaccino attenuato vivo per la protezione da infezioni di b.bronchiseptica e vaccino ar vivo
PL348550A1 (en) Ibdv mutant, vaccine containing it for protecting poultry against a disease caused by ibdv and method of protecting poultry against such disease
WO1998050067A3 (de) Verwendung eines sekretionsvektors zur fertilitätskontrolle durch orale vakzinierung
AR007262A1 (es) Preparacion de una vacuna no convencional contra la mancha